Yeast Protein for Muscle Mass
Yeast Protein for Muscle Anabolism: A Randomized Controlled Trial
調査の概要
状態
条件
詳細な説明
This is a double-blinded randomized clinical trial of a 16-week nutrition intervention with yeast and whey protein in 72 people (36 per group; 18 male and 18 female) between the ages of 18 and 35, recruited from the University of Alberta campus, Edmonton, Canada. Consenting participants will be randomly assigned to one of two groups: whey protein or yeast protein by the study coordinator, who will not collect study outcome measurements or analyze the data.
The goal of the trial is to determine if consumption of 40 g per day of yeast protein produces similar effects to 40 g supplementation with whey protein. It is anticipated that daily yeast protein consumption will show similar gains in muscle mass and improvement in immune function, increased diversity in gut microbiota, and amino acid-derived metabolites compared to whey protein.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Jianping Wu, PhD
- 電話番号:(780) 492-6885
- メール:jwu3@ualberta.ca
研究場所
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 2R3
- The University of Alberta North Campus
-
コンタクト:
- Jianping Wu, PhD
- 電話番号:(780) 492-6885
- メール:jwu3@ualberta.ca
-
主任研究者:
- Jianping Wu, PhD
-
主任研究者:
- Vera Mazurak, PhD
-
主任研究者:
- Normand Bouleé, PhD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Participants must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.
- Prior resistance training experience (defined as performing resistance exercises >1/week for the past 3 months or longer) to enable them to reach a large training stimulus relatively quickly and to avoid the longer phase of neuromuscular adaptations
- ≥18 years and <35 years of age
Exclusion Criteria:
- Diabetes, musculoskeletal disease, cancer, Crohn's disease, or any other acute or chronic condition that interferes (or the medication prescribed for those conditions) with muscle anabolism.
- Diagnosed with or being treated for heart disease, stroke, high blood pressure 130/80 mmHg or higher
- Pain/discomfort/pressure in the chest during activities of daily living or physical activity
- Pregnant or not on adequate contraception.
- A known hypersensitivity/allergy to ingredients in the supplements.
- Inflammatory bowel diseases
- Enrolment in any other clinical protocol or investigational study that may interfere with study procedures
- Taking antibiotics
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:乳漿タンパク
|
Lower and upper body resistance training exercises 3 times a week for 16 weeks
60g of protein supplement (40g of protein).
Oral administration, 30g during exercise and anytime after exercise, or 30g in the morning and evening if no exercise is performed for a period of 16 weeks.
|
|
実験的:Yeast Protein
|
Lower and upper body resistance training exercises 3 times a week for 16 weeks
60g of protein supplement (40g of protein).
Oral administration, 30g during exercise and anytime after exercise, or 30g in the morning and evening if no exercise is performed for a period of 16 weeks.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in muscle mass
時間枠:16 weeks
|
The primary outcome of the study is the change in muscle mass.
It is hypothesized that participants consuming yeast protein will show an increase in appendicular lean mass similar to that observed with whey protein.
|
16 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in muscle function, inflammatory biomarkers, oxidative stress markers, gut microbiota and metabolites
時間枠:16 weeks
|
The secondary outcomes of the study include changes in muscle function, which will be assessed through one repetition maximum (1RM) testing for both the bench press and leg press.
Additionally, the investigators will evaluate inflammatory biomarkers, specifically plasma cytokines, as well as oxidative stress markers such as glutathione, total antioxidant capacity, and protein carbonyl levels.
The study will also investigate gut microbiota and metabolites.
The investigators hypothesize that the secondary outcomes will show similar effects in participants taking yeast protein compared to those taking whey protein.
|
16 weeks
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012 Dec;96(6):1454-64. doi: 10.3945/ajcn.112.037556. Epub 2012 Nov 7.
- Patel S. Emerging trends in nutraceutical applications of whey protein and its derivatives. J Food Sci Technol. 2015 Nov;52(11):6847-58. doi: 10.1007/s13197-015-1894-0. Epub 2015 Jun 9.
- West DWD, Abou Sawan S, Mazzulla M, Williamson E, Moore DR. Whey Protein Supplementation Enhances Whole Body Protein Metabolism and Performance Recovery after Resistance Exercise: A Double-Blind Crossover Study. Nutrients. 2017 Jul 11;9(7):735. doi: 10.3390/nu9070735.
- Norton LE, Wilson GJ, Layman DK, Moulton CJ, Garlick PJ. Leucine content of dietary proteins is a determinant of postprandial skeletal muscle protein synthesis in adult rats. Nutr Metab (Lond). 2012 Jul 20;9(1):67. doi: 10.1186/1743-7075-9-67.
- Joy JM, Lowery RP, Wilson JM, Purpura M, De Souza EO, Wilson SM, Kalman DS, Dudeck JE, Jager R. The effects of 8 weeks of whey or rice protein supplementation on body composition and exercise performance. Nutr J. 2013 Jun 20;12:86. doi: 10.1186/1475-2891-12-86.
- Banaszek A, Townsend JR, Bender D, Vantrease WC, Marshall AC, Johnson KD. The Effects of Whey vs. Pea Protein on Physical Adaptations Following 8-Weeks of High-Intensity Functional Training (HIFT): A Pilot Study. Sports (Basel). 2019 Jan 4;7(1):12. doi: 10.3390/sports7010012.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Pro00156043
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。